Format

Send to

Choose Destination
See comment in PubMed Commons below
Biochem Biophys Res Commun. 2005 Oct 7;335(4):1173-8.

The influence of HER2 genotypes as molecular markers in ovarian cancer outcome.

Author information

  • 1Pathology and Molecular Oncology Unit, Portuguese Institute of Oncology, Porto, Portugal. patpriv@ipoporto.min-saude.pt

Abstract

A relevant clinical problem in the treatment of ovarian cancer (OC) is the development of resistance to chemotherapy, frequently due to genetic variations in enzymes and receptors. Changes in the HER2 receptor have been associated with breast and ovarian cancers. The role of a polymorphism in the HER2 gene in the clinical outcome of OC patients was investigated in this study. We characterized DNA samples from 111 patients with OC treated with cisplatin and paclitaxel, using PCR-RFLP. Our results indicate that patients carrying the valine homozygotic genotype present a lower overall survival mean, suggesting a role for this polymorphism in the outcome of ovarian cancer patients. The G allele has been implicated in the formation of active HER2 receptors, with a more aggressive phenotype. We hypothesize that HER2 genotypes can be predictive biomarkers in ovarian cancer, contributing to a genetic individual profile of great interest in clinical oncology.

PMID:
16112085
DOI:
10.1016/j.bbrc.2005.08.012
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center